This is a working overview of half-life, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
13 November White faces generated by artificial intelligence (AI) are perceived as more real than actual human faces while the same is not true for people of colour in a study. A study proposes characteristics of human evolution underlie current global environmental problems, favoring groups of increased size and group-level cultural traits of greater environmental exploitation. Based on the hypothesis that the primary mechanism of evolutionary inheritance has shifted from genes to culture, it suggests cultural evolution patterns to date work against global collective solutions to Anthropocene challenges. An umbrella review summarizes the research on benefits and risks associated with digital media use by youths, suggesting caregivers, policymakers and researchers should continue to move away from prevailing oversimplified recommendations to reduce screen time to instead focus on the types of screen use. 15 November Geologists report that Iceland may face "decades" of volcanic instability, following a series of recent eruptions on the Reykjanes Peninsula, breaking an 800-year hiatus. 3D printing of hair follicles on lab-grown skin is reported. 16 November Casgevy, a world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent beta thalassemia, is approved by the UK's Medicines and Healthcare products Regulatory Agency, becoming the first drug using CRISPR to be licensed. Scientists report first evidence that unfamiliar groups of nonhuman primates, particularly bonobos, are capable of cooperating with each other.
=== Databases === As continual research on the properties of supplements accumulates, databases or fact sheets for various supplements are updated regularly, including the Dietary Supplement Label Database, Dietary Supplement Ingredient Database, and Dietary Supplement Facts Sheets of the United States. In Canada where a license is issued when a supplement product has been proven by the manufacturer and government to be safe, effective and of sufficient quality for its recommended use, an eight-digit Natural Product Number is assigned and recorded in a Licensed Natural Health Products Database. The European Food Safety Authority maintains a compendium of botanical ingredients used in manufacturing of dietary supplements. In 2015, the Australian Government's Department of Health published the results of a review of herbal supplements to determine if any were suitable for coverage by health insurance. Establishing guidelines to assess safety and efficacy of botanical supplement products, the European Medicines Agency provided criteria for evaluating and grading the quality of clinical research in preparing monographs about herbal supplements. In the United States, the National Center for Complementary and Integrative Health of the National Institutes of Health provides fact sheets evaluating the safety, potential effectiveness and side effects of many botanical products.
== Alternatives to EDTA == Interest in environmental safety has raised concerns about biodegradability of aminopolycarboxylates such as EDTA. These concerns incentivize the investigation of alternative aminopolycarboxylates. Candidate chelating agents include nitrilotriacetic acid (NTA), iminodisuccinic acid (IDS), polyaspartic acid, S,S-ethylenediamine-N,N′-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), and L-Glutamic acid N,N-diacetic acid, tetrasodium salt (GLDA).
Damp (or wet) is defined as the condition of an aggregate in which water is fully permeated the aggregate through the pores in it, and there is free water in excess of the SSD condition on its surfaces which will become part of the mixing water.
=== Screening glucose challenge test === The screening glucose challenge test (sometimes called the O'Sullivan test) is performed between 24 and 28 weeks and can be seen as a simplified version of the oral glucose tolerance test (OGTT). No previous fasting is required for this screening test, in contrast to the OGTT. The O'Sullivan test involves drinking a solution containing 50 grams of glucose and measuring blood levels one hour later. If the cut-off point is set at 140 mg/dL (7.8 mmol/L), 80% of women with GDM will be detected. If this threshold for further testing is lowered to 130 mg/dL, 90% of GDM cases will be detected, but there will also be more women who will be subjected to a consequent OGTT unnecessarily.
Sources: en.wikipedia.org
The adenosine nucleotide binding site is located between two beta hairpin-shaped structures pertaining to the I and III domains. The residues that are involved are Asp11-Lys18 and Asp154-His161 respectively. The divalent cation binding site is located just below that for the adenosine nucleotide. In vivo it is most often formed by Mg2+ or Ca2+ while in vitro it is formed by a chelating structure made up of Lys18 and two oxygens from the nucleotide's α-and β-phosphates. This calcium is coordinated with six water molecules that are retained by the amino acids Asp11, Asp154, and Gln137. They form a complex with the nucleotide that restricts the movements of the so-called "hinge" region, located between residues 137 and 144. This maintains the native form of the protein until its withdrawal denatures the actin monomer. This region is also important because it determines whether the protein's cleft is in the "open" or "closed" conformation. It is highly likely that there are at least three other centres with a lesser affinity (intermediate) and still others with a low affinity for divalent cations. It has been suggested that these centres may play a role in the polymerization of actin by acting during the activation stage. There is a structure in subdomain 2 that is called the "D-loop" because it binds with DNase I, it is located between the His40 and Gly48 residues. It has the appearance of a disorderly element in the majority of crystals, but it looks like a β-sheet when it is complexed with DNase I.
=== Mexico === Mexico is estimated to be the world's third largest producer of opium with poppy cultivation. It also is a major supplier of heroin and the largest foreign supplier of marijuana, cocaine and methamphetamine to the U.S. market. These drugs are supplied by Drug Trafficking Organizations (DTOs). The U.S. government estimates that Mexican DTOs gain tens of billions of dollars each year from drug sales in the U.S. alone. DTOs are continually battling for control of territory in Mexico used for the cultivation, importation and transportation of illicit drugs. The U.S. government considers groups affiliated with DTOs a significant threat to the safety within the U.S. The Drug Enforcement Administration (DEA) enforces 'the controlled substances laws and regulations of the US and pursues organizations and members involved in the growing, manufacture, or distribution of controlled substances appearing in or destined for illicit traffic in the U.S.'. The Mexican DTOs that pose the biggest threat to the US, according to the DEA, are the Sinaloa Cartel, Jalisco New Generation Cartel, Juarez Cartel, Gulf Cartel, Los Zetas Cartel and the Beltran-Leyva Organization. In 2007, the U.S. launched the Merida initiative, a bilateral partnership that supports Mexico's law enforcement, helps to counteract the illegal trade in narcotics and strengthens border security. The four main focuses of this initiative are 'disrupting organized criminal groups; institutionalizing the rule of law; creating a 21st-century border, and building strong and resilient communities'.
P. s. pv. aceris attacks maple Acer species. P. s. pv. actinidiae attacks kiwifruit Actinidia chinensis. P. s. pv. aesculi attacks horse chestnut Aesculus hippocastanum, causing bleeding canker. P. s. pv. aptata attacks beets Beta vulgaris. P. s. pv. atrofaciens attacks wheat Triticum aestivum. P. s. pv. dysoxylis attacks the kohekohe tree Dysoxylum spectabile. P. s. pv. glycinea attacks soybean Glycine max, causing bacterial blight of soybean. P. s. pv. japonica attacks barley Hordeum vulgare. P. s. pv. lapsa attacks wheat Triticum aestivum. P. s. pv. panici attacks Panicum grass species. P. s. pv. papulans attacks crabapple Malus sylvestris species. P. s. pv. persicae attacks nectarine and peach. P. s. pv. phaseolicola causes halo blight of beans. P. s. pv. pisi attacks peas Pisum sativum. P. s. pv. syringae attacks Syringa, Prunus, and Phaseolus species. P. s. pv. tomato attacks tomato. However, many of the strains for which new species groupings were proposed continue to be referred to in the scientific literature as pathovars of P. syringae, including pathovars tomato, phaseolicola, and maculicola. Pseudomonas savastanoi was once considered a pathovar or subspecies of P. syringae, and in many places continues to be referred to as P. s. pv. savastanoi, although as a result of DNA-relatedness studies, it has been instated as a new species. It has three host-specific pathovars: P. s. fraxini (which causes ash canker), P. s. nerii (which attacks oleander), and P. s. oleae (which causes olive knot).
== Personal life == Collins lives in Roxwell, Chelmsford in a barn conversion which she bought for £1.35 million in 2021. She has described the house as her "dream home" and has had multiple renovations including a swimming pool and a summer house. Collins enjoys gardening and has expressed her love of plants, as well as her passion for animals and nature. She has two dogs and two cats, as well as chickens. Collins has several life-size animal sculptures inside her home and in her garden, including a horse with a disco ball and a giraffe lamp, as well as a wooden Asian mother elephant and its calf, the former of which she donated £22,000 to CoExistence, an environmental art campaign conceptualised by the Elephant Family.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.